Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MECP2 | P51608 | 1/20 | 0.40 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.40 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.40 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.40 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22599687 | 1.00 | METAP1 (0.48) | METAP1NPC1RAB9ANPY5RSLC2A1 | |
| SCHEMBL30000401 | 0.82 | KCNN1 (0.57) | NPC1RAB9ASLC2A1KMT2AMECP2 | |
| SCHEMBL22583068 | 0.82 | KCNN1 (0.57) | NPC1RAB9ASLC2A1KMT2AMECP2 | |
| SCHEMBL30000393 | 0.81 | TRPV4 (0.42) | CCR6KMT2ATRPV1PTGS1 | |
| SCHEMBL22583590 | 0.81 | TRPV4 (0.42) | CCR6KMT2ATRPV1PTGS1 | |
| SCHEMBL22583150 | 0.80 | CCR1 (0.39) | CCR6KMT2ATRPV1MAPK3 | |
| SCHEMBL6368472 | 0.80 | NPY5R (0.72) | NPC1RAB9ANPY5RSLC2A1KMT2A | |
| SCHEMBL30745709 | 0.80 | NPY5R (0.72) | NPC1RAB9ANPY5RSLC2A1KMT2A | |
| SCHEMBL22583454 | 0.80 | SMN1; SMN2 (0.48) | NPC1RAB9ASLC2A1KMT2AMECP2 | |
| SCHEMBL30000981 | 0.80 | SMN1; SMN2 (0.48) | NPC1RAB9ASLC2A1KMT2AMECP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | claimed |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2022-11-22 | — | — | US | claimed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | METAP1 2910/4885NPC1 857/4885RAB9A 839/4885 |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | METAP1 2910/4885NPC1 857/4885RAB9A 839/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | METAP1 2910/4885NPC1 857/4885RAB9A 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.